Form 4: Fulgent Genetics' Chief Scientific Officer Gao Hanlin Reports Stock Transaction
SEC Form 4 Filing
Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, reports a transaction involving the withholding of shares to cover tax obligations.
Summary
- On October 30, 2024, Fulgent Genetics' Chief Scientific Officer, Gao Hanlin, had 79 shares of common stock withheld to cover tax obligations.
- The shares were withheld at a price of $20.27 per share.
- Following the transaction, Gao Hanlin directly owns 921,339 shares of Fulgent Genetics common stock.
Sentiment
Score: 5
Explanation: This is a neutral filing related to standard tax withholding procedures, with no significant positive or negative implications.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates a standard tax withholding procedure related to vested stock.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine tax withholding.
Key Dates
| Date | Description |
|---|---|
| 04/30/2021 | Date of grant of restricted stock units to Gao Hanlin. |
| 10/30/2024 | Date of the stock transaction (tax withholding). |
| 11/01/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.